A 52 Week Randomized, Controlled, Open Label, Multicenter, Multinational, Parallel, Treat to Target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily

Grants and Contracts Details

StatusFinished
Effective start/end date9/1/098/31/11

Funding

  • Novo Nordisk Pharmaceuticals Inc: $122,469.00